First-in-human global studies initiated for ZW191, an antibody-drug conjugate (ADC) engineered to target folate receptor-? (FR?) and ZW171, a bispecific 2 + 1 T cell engager (TCE) targeting mesothelin ...

Labroots’ virtual events are designed to spark impactful scientific discussions while connecting with individuals worldwide ...

First-in-human global studies initiated for ZW191, an antibody-drug conjugate (ADC) engineered to target folate receptor-⍺ (FR⍺) and ZW171, a ...

Top-line results from SUMMIT trial in NonAdvSM patients expected July 2025• APEX trial enrollment in AdvSM patients complete; top-line results ...

A team from University Hospitals Seidman Cancer Center is launching the nation's first-ever clinical trials evaluating the cholesterol drug ... after an investigational new drug application ...

Findings support the development of a novel peptide vaccine targeting the immunosuppressive effects of Transforming Growth Beta (TGF-β) in solid tumors NEW YORK, Feb. 23, 2025 (GLOBE NEWSWIRE) -- IO ...

Ionis Pharmaceuticals, Inc. today announced that it will present additional data from the pivotal Phase 3 OASIS and OASISplus studies, as well as three year data from the Phase 2 open-label extension ...

"It's also important to understand that these new drugs are only beneficial for individuals in the early stages of the disease," the doctor, who is also medical director at Remo Health in ...

Foster City: Gilead Sciences, Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA ... to expedite the development and regulatory review of ...

The Breakthrough Therapy Designation process is intended to expedite the development and regulatory review of investigational ... announced that the U.S. Food and Drug Administration (FDA) has ...

Zabalafin Hydrogel is a novel, first-in-class complex single-source botanical drug with multiple bioactive compounds that provide multiple mechanisms of action, including anti-pruritic (anti-itch ...

Efficacy of nivolumab plus ipilimumab in T1aN0M0 renal cell carcinoma (RCC) patients: Results from 3-year follow-up of the phase 2 pilot study. Efficacy outcomes with belzutifan versus everolimus by ...